Subscribe to RSS
DOI: 10.1055/s-0034-1389986
Short-term Curcuminoid Supplementation for Chronic Pulmonary Complications due to Sulfur Mustard Intoxication: Positive Results of a Randomized Double-blind Placebo-controlled Trial
Publication History
received 03 July 2014
accepted 21 August 2014
Publication Date:
30 September 2014 (online)
![](https://www.thieme-connect.de/media/drugres/201511/lookinside/thumbnails/2014-07-0786_10-1055-s-0034-1389986-1.jpg)
Abstract
Pulmonary problems are among the most frequent chronic complications of sulfur mustard (SM) intoxication and are often accompanied by deregulated production of pro-inflammatory cytokines. Curcuminoids, comprising curcumin, demethoxycurcumin and bisdemethoxycurcumin, are phytochemicals with remarkable anti-inflammatory properties that are derived from dried rhizomes of the plant Curcuma longa L. (turmeric). The present pilot study aimed to investigate the clinical effects of supplementation with curcuminoids on markers of pulmonary function and systemic inflammation in SM-intoxicated subjects. In a randomized double-blind placebo-controlled trial, 89 male subjects who were suffering from chronic SM-induced pulmonary complications were recruited and assigned to either curcuminoids (500 mg TID per oral; n=45) or placebo (n=44) for a period of 4 weeks. Efficacy measures were changes in the spirometric parameters (FVC, FEV1, FEV1/FVC) and serum levels of inflammatory mediators including interleukins 6 (IL-6) and 8 (IL-8), tumor necrosis factor-α (TNFα), transforming growth factor-β (TGFβ), high-sensitivity C-reactive protein (hs-CRP), calcitonin gene related peptide (CGRP), substance P and monocyte chemotactic protein-1 (MCP-1). 78 subjects completed the trial. Although FEV1 and FVC remained comparable between the groups, there was a greater effect of curcuminoids vs. placebo in improving FEV1/FVC (p=0.002). Curcuminoids were also significantly more efficacious compared to placebo in modulating all assessed inflammatory mediators: IL-6 (p<0.001), IL-8 (p=0.035), TNFα (p<0.001), TGFβ (p<0.001), substance P (p=0.016), hs-CRP (p<0.001), CGRP (p<0.001) and MCP-1 (p<0.001). Curcuminoids were safe and well-tolerated throughout the trial. Short-term adjunctive therapy with curcuminoids can suppress systemic inflammation in patients suffering from SM-induced chronic pulmonary complications.
-
References
- 1 Balali-Mood M, Hefazi M, Mahmoudi M et al. Long-term complications of sulphur mustard poisoning in severely intoxicated Iranian veterans. Fundam Clin Pharmacol 2005; 19: 713-721
- 2 Khateri S, Ghanei M, Keshavarz S et al. Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J Occup Environ Med 2003; 45: 1136-1143
- 3 Emad A, Rezaian GR. The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: analysis of 197 cases. Chest 1997; 112: 734-738
- 4 Attaran D, Khajedaloui M, Jafarzadeh R et al. Health-related quality of life in patients with chemical warfare-induced chronic obstructive pulmonary disease. Arch Iran Med 2006; 9: 359-363
- 5 Balali-Mood M, Hefazi M. Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic Clin Pharmacol Toxicol 2006; 99: 273-282
- 6 Ghanei M, Fathi H, Mohammad MM et al. Long-term respiratory disorders of claimers with subclinical exposure to chemical warfare agents. Inhal Toxicol 2004; 16: 491-495
- 7 Vernooy JH, Kucukaycan M, Jacobs JA et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002; 166: 1218-1224
- 8 Polatli M, Cakir A, Cildag O et al. Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis 2008; 26: 97-102
- 9 Tonstad S, Cowan JL. C-reactive protein as a predictor of disease in smokers and former smokers: a review. Int J Clin Pract 2009; 63: 1634-1641
- 10 Westergren-Thorsson G, Larsen K, Nihlberg K et al. Pathological airway remodelling in inflammation. Clin Respir J 2010; 4 (Suppl. 01) 1-8
- 11 MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 2001; 429: 195-207
- 12 Tkacova R, Kluchova Z, Joppa P et al. Systemic inflammation and systemic oxidative stress in patients with acute exacerbations of COPD. Respir Med 2007; 101: 1670-1676
- 13 Attaran D, Lari SM, Khajehdaluee M et al. Highly sensitive C-reactive protein levels in Iranian patients with pulmonary complication of sulfur mustard poisoning and its correlation with severity of airway diseases. Human & experimental toxicology 2009; 28: 739-745
- 14 Attaran D, Lari SM, Towhidi M et al. Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease 2010; 5: 335-340
- 15 Panahi Y, Davoudi SM, Sahebkar A et al. Efficacy of Aloe vera/olive oil cream versus betamethasone cream for chronic skin lesions following sulfur mustard exposure: a randomized double-blind clinical trial. Cutaneous and ocular toxicology 2012; 31: 95-103
- 16 Panahi Y, Ghanei M, Vahedi E et al. Effect of recombinant human IFNgamma in the treatment of chronic pulmonary complications due to sulfur mustard intoxication. Journal of immunotoxicology 2013;
- 17 Panahi Y, Sahebkar A, Davoudi SM et al. Efficacy and safety of immunotherapy with interferon-gamma in the management of chronic sulfur mustard-induced cutaneous complications: comparison with topical betamethasone 1%. TheScientificWorldJournal 2012; 2012: 285274
- 18 Panahi Y, Sarayani A, Beiraghdar F et al. Management of sulfur mustard-induced chronic pruritus: a review of clinical trials. Cutaneous and ocular toxicology 2012; 31: 220-225
- 19 Sahebkar A. Baicalin as a potentially promising drug for the management of sulfur mustard induced cutaneous complications: a review of molecular mechanisms. Cutaneous and ocular toxicology 2012; 31: 226-234
- 20 Anand P, Kunnumakkara AB, Newman RA et al. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807-818
- 21 Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxidants & redox signaling 2008; 10: 511-545
- 22 Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?. BioFactors 2013; 39: 197-208
- 23 Shehzad A, Khan S, Sup Lee Y. Curcumin molecular targets in obesity and obesity-related cancers. Future Oncol 2012; 8: 179-190
- 24 Sahebkar A. Molecular mechanisms for curcumin benefits against ischemic injury. Fertility and sterility 2010; 94: e75-e76 author reply e7
- 25 Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009; 14: 141-153
- 26 Shehzad A, Ha T, Subhan F et al. New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. Eur J Nutr 2011; 50: 151-161
- 27 Shehzad A, Rehman G, Lee YS. Curcumin in inflammatory diseases. BioFactors 2013; 39: 69-77
- 28 Sahebkar A. Are Curcuminoids Effective C-Reactive Protein-Lowering Agents in Clinical Practice? Evidence from a Meta-Analysis. Phytotherapy research 2014; 28: 633-642
- 29 Meng B, Li J, Cao H. Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications. Current pharmaceutical design 2013; 19: 2101-2113
- 30 Sahebkar A, Mohammadi A, Atabati A et al. Curcuminoids Modulate Pro-Oxidant-Antioxidant Balance but not the Immune Response to Heat Shock Protein 27 and Oxidized LDL in Obese Individuals. Phytotherapy research 2013; 27: 1883-1888
- 31 Hossain DM, Bhattacharyya S, Das T et al. Curcumin: the multi-targeted therapy for cancer regression. Frontiers in bioscience 2012; 4: 335-355
- 32 Shehzad A, Wahid F, Lee YS. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Archiv der Pharmazie 2010; 343: 489-499
- 33 Srivastava G, Mehta JL. Currying the heart: curcumin and cardioprotection. Journal of cardiovascular pharmacology and therapeutics 2009; 14: 22-27
- 34 Srivastava RM, Singh S, Dubey SK et al. Immunomodulatory and therapeutic activity of curcumin. International immunopharmacology 2011; 11: 331-341
- 35 Monroy A, Lithgow GJ, Alavez S. Curcumin and neurodegenerative diseases. BioFactors 2013; 39: 122-132
- 36 Panahi Y, Badeli R, Karami N et al. Investigation of the Efficacy of Adjunctive Therapy with Bioavailability-Boosted Curcuminoids in Major Depressive Disorder. Phytother Res 2014; 4 DOI: 10.1002/ptr.5211.
- 37 Coban D, Milenkovic D, Chanet A et al. Dietary curcumin inhibits atherosclerosis by affecting the expression of genes involved in leukocyte adhesion and transendothelial migration. Molecular nutrition & food research 2012; 56: 1270-1281
- 38 Mohammadi A, Sahebkar A, Iranshahi M et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytotherapy research: PTR 2013; 27: 374-379
- 39 Panahi Y, Khalili N, Hosseini MS et al. Lipid-modifying effects of adjunctive therapy with curcuminoids – piperine combination in patients with metabolic syndrome: Results of a randomized controlled trial. Complement Ther Med 2014; DOI: 10.1016/j.ctim.2014.07.006.
- 40 Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer letters 2008; 269: 199-225
- 41 Panahi Y, Rahimnia AR, Sharafi M et al. Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res 2014; DOI: 10.1002/ptr.5174.
- 42 Ghanei M, Ghayumi M, Ahakzani N et al. Noninvasive diagnosis of bronchiolitis obliterans due to sulfur mustard exposure: could high-resolution computed tomography give us a clue?. La Radiologia medica 2010; 115: 413-420
- 43 Panahi Y, Ghanei M, Aslani J et al. The therapeutic effect of gamma interferon in chronic bronchiolitis due to mustard gas. Iranian journal of allergy, asthma, and immunology 2005; 4: 83-90
- 44 Suzuki M, Betsuyaku T, Ito Y et al. Curcumin attenuates elastase- and cigarette smoke-induced pulmonary emphysema in mice. American journal of physiology Lung cellular and molecular physiology 2009; 296: L614-L623
- 45 Venkatesan N. Pulmonary protective effects of curcumin against paraquat toxicity. Life sciences 2000; 66: PL21-PL28
- 46 Kalpana C, Menon VP. Curcumin ameliorates oxidative stress during nicotine-induced lung toxicity in Wistar rats. The Italian journal of biochemistry 2004; 53: 82-86
- 47 Punithavathi D, Venkatesan N, Babu M. Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. British journal of pharmacology 2000; 131: 169-172
- 48 Punithavathi D, Venkatesan N, Babu M. Protective effects of curcumin against amiodarone-induced pulmonary fibrosis in rats. British journal of pharmacology 2003; 139: 1342-1350
- 49 Vanisree AJ, Sudha N. Curcumin combats against cigarette smoke and ethanol-induced lipid alterations in rat lung and liver. Molecular and cellular biochemistry 2006; 288: 115-123
- 50 Xu M, Deng B, Chow YL et al. Effects of curcumin in treatment of experimental pulmonary fibrosis: a comparison with hydrocortisone. Journal of ethnopharmacology 2007; 112: 292-299
- 51 Polasa K, Raghuram TC, Krishna TP et al. Effect of turmeric on urinary mutagens in smokers. Mutagenesis 1992; 7: 107-109
- 52 Sin DD, Man SF. Interleukin-6: a red herring or a real catch in COPD?. Chest 2008; 133: 4-6
- 53 Yanbaeva DG, Dentener MA, Spruit MA et al. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case-control study. BMC medical genetics 2009; 10: 23
- 54 Emad A, Emad Y. Levels of cytokine in bronchoalveolar lavage (BAL) fluid in patients with pulmonary fibrosis due to sulfur mustard gas inhalation. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research 2007; 27: 38-43
- 55 Oh SW, Cha JY, Jung JE et al. Curcumin attenuates allergic airway inflammation and hyper-responsiveness in mice through NF-kappaB inhibition. Journal of ethnopharmacology 2011; 136: 414-421
- 56 Shakibaei M, John T, Schulze-Tanzil G et al. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. Biochemical pharmacology 2007; 73: 1434-1445
- 57 Jobin C, Bradham CA, Russo MP et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. Journal of immunology 1999; 163: 3474-3483
- 58 Shishodia S, Amin HM, Lai R et al. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochemical pharmacology 2005; 70: 700-713
- 59 Surh YJ, Chun KS, Cha HH et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutation research 2001; 480-481: 243-268
- 60 Abe Y, Hashimoto S, Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacological research: the official journal of the Italian Pharmacological Society 1999; 39: 41-47
- 61 Biswas SK, McClure D, Jimenez LA et al. Curcumin induces glutathione biosynthesis and inhibits NF-kappaB activation and interleukin-8 release in alveolar epithelial cells: mechanism of free radical scavenging activity. Antioxidants & redox signaling 2005; 7: 32-41
- 62 Holroyde MC, Altounyan RE, Cole M et al. Bronchoconstriction produced in man by leukotrienes C and D. Lancet 1981; 2: 17-18
- 63 Lam S, Chan H, LeRiche JC et al. Release of leukotrienes in patients with bronchial asthma. The Journal of allergy and clinical immunology 1988; 81: 711-717
- 64 Marom Z, Shelhamer JH, Sun F et al. Human airway monohydroxyeicosatetraenoic acid generation and mucus release. The Journal of clinical investigation 1983; 72: 122-127
- 65 Panahi Y, Sahebkar A, Amiri M et al. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. The British journal of nutrition 2012; 108: 1272-1279
- 66 Panahi Y, Sahebkar A, Parvin S et al. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Annals of clinical biochemistry 2012; 49: 580-588
- 67 Cheng AL, Hsu CH, Lin JK et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer research 2001; 21: 2895-2900
- 68 Lao CD, Ruffin MTt, Normolle D et al. Dose escalation of a curcuminoid formulation. BMC complementary and alternative medicine 2006; 6: 10
- 69 Shoba G, Joy D, Joseph T et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta medica 1998; 64: 353-356
- 70 Kim DH, Phillips JF, Lockey RF. Oral curcumin supplementation in patients with atopic asthma. Allergy & rhinology 2011; 2: e51-e53